Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Pemvidutide, an investigational dual-pathway therapy, demonstrates sustained metabolic improvements across liver function, lipid profiles, and cardiovascular risk markers in a 48-week Phase 2b trial. The data suggest a mechanistic advantage over single-pathway GLP-1 agents by addressing the interconnected metabolic dysfunction underlying fatty liver disease and cardiovascular risk.
Traditional risk factors—age, sex, smoking, alcohol consumption, waist-to-hip ratio, and BMI—predict chronic disease incidence more accurately than epigenetic clocks in middle-aged adults over 7–9 years. This finding challenges the clinical utility of epigenetic aging biomarkers without demonstrated incremental value over conventional assessment.
HRS-7535, an oral GLP-1 receptor agonist, demonstrated 11.1% weight loss at 44 weeks in Phase 3 trials with a favorable safety profile dominated by mild-to-moderate gastrointestinal effects. The drug also showed non-inferiority to dapagliflozin in type 2 diabetes management while producing larger HbA1c reductions, positioning it as an alternative to injectable agents in metabolic disease treatment.
LG AI Research and D&D Pharmatech are partnering to use artificial intelligence to design peptide therapeutics, compressing the molecular discovery timeline by generating novel candidates based on pattern recognition rather than manual search. This collaboration addresses both the design challenge and the delivery barrier that has limited peptide drug development, positioning AI as an active research participant rather than a background tool.
Sarcopenia and osteoporosis share bidirectional risk pathways mediated by inflammation, metabolic dysfunction, and genetic factors related to mitochondrial function and immune regulation. This integrated mechanism suggests that addressing muscle and bone loss requires simultaneous intervention on shared biological drivers rather than treating them as separate conditions.
RNA expression—not static DNA—reveals real-time shifts in how your body responds to food, stress, and environment. Combined with microbiome analysis and AI-driven interpretation of biomarkers, this approach enables personalized nutrition and health optimization rather than population-level dietary prescriptions that often fail at the individual level.
Pemvidutide, a dual glucagon/GLP-1 receptor agonist, demonstrated sustained reductions in cardiometabolic risk factors and liver fibrosis over 48 weeks in patients with metabolic dysfunction-associated steatohepatitis. This positions the compound as a potential therapeutic option in a therapeutic area where metabolic and hepatic dysfunction often progress in parallel.
Age-related changes in the gut epithelium, enteric nervous system, and microbiota interact to accelerate intestinal aging. Organoid research demonstrates that microbial metabolites from aged animals can transfer aging characteristics to young epithelial tissue, suggesting the microbiota plays a direct role in intestinal senescence.
June 2026 research advances reveal multiple pathways through which cellular dysfunction drives age-related disease: protein disposal failures in neurodegeneration, immune system weakening of microbiome control, senescent cell accumulation promoting inflammation and cancer, and epigenetic dysregulation affecting vascular and metabolic health. These findings converge on a mechanistic understanding of how aging at the cellular level translates into clinical disease, with several studies demonstrating that targeted interventions—from gene therapy to selective senescent cell removal—can extend lifespan and healthspan in preclinical models.
Designs for Health has launched Akkermansia Pro GLP-1 Probiotic, combining live Akkermansia muciniphila with a clinically studied postbiotic (BPL1) to support metabolic health, blood sugar control, and body composition. This product represents a shift in the microbiome industry away from generic digestive probiotics toward targeted metabolic interventions informed by emerging research on gut-metabolism signaling.
Spatial proteomics mapping of aged mouse gut tissue reveals localized accumulation of senescent immune cells near the epithelial barrier, metabolic reprogramming through mTOR upregulation, and compartment-specific immune exhaustion in lymphoid regions. These interconnected molecular alterations indicate progressive dysregulation of intestinal immune homeostasis, with direct implications for age-related loss of mucosal barrier resilience.
Generation Lab released SystemAge 2.1, a biological age test measuring 460+ biomarkers across 21 organ systems with sex-specific analysis and 99% validated accuracy. The platform tracks organ-level aging trajectories and quantifies treatment response to interventions including stem cells and plasma exchange, enabling practitioners to detect accelerated aging earlier and monitor intervention efficacy with precision.